Build a lasting personal brand

Cardio Diagnostics Sets Dec. 10 Investor Call to Detail Cardiovascular Testing Advances and FDA Breakthrough Device Plans

By Burstable Editorial Team•
Cardio Diagnostics Holdings (NASDAQ: CDIO) will host a Dec. 10 investor call to update shareholders on its precision cardiovascular tests, reimbursement progress, international expansion into India, and plans to seek FDA Breakthrough Device designation for its non-obstructive coronary artery disease detection technology.
Cardio Diagnostics Sets Dec. 10 Investor Call to Detail Cardiovascular Testing Advances and FDA Breakthrough Device Plans

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) has scheduled an investor conference call for Dec. 10, 2026, at 11 a.m. CT to provide updates on its precision cardiovascular disease detection and prevention technologies, the company announced. The call will cover its commercially available Epi+Gen CHD™ and PrecisionCHD™ tests, ongoing and planned studies, reimbursement progress, and strategic growth initiatives, with particular emphasis on non-obstructive coronary artery disease (NOCAD), a condition that can be missed by conventional diagnostic methods.

Management plans to present data supporting its blood-based technology for detecting NOCAD and to discuss its anticipated request for U.S. Food and Drug Administration (FDA) Breakthrough Device designation. That designation, if granted, could expedite regulatory review and help bring the company's NOCAD detection approach to market faster. The call will also address the commencement of testing in India, Cardio Diagnostics' first international market, through partnerships with Dr. Lal PathLabs and Aimil.

The announcement matters because cardiovascular disease remains a leading cause of death globally, and NOCAD often goes undetected by standard diagnostic tools, leaving patients at risk without appropriate intervention. Cardio Diagnostics' approach combines epigenetics, genetics, and artificial intelligence to provide scalable cardiovascular risk assessment and early disease detection through standard blood samples. If its technology proves effective in detecting NOCAD, it could broaden access to early diagnosis and enable more personalized prevention strategies.

For investors, the Dec. 10 call offers a window into the company's clinical and commercial momentum, including reimbursement progress that is critical to adoption. The India testing initiative represents the company's first international expansion and could open additional revenue opportunities. The potential FDA Breakthrough Device request signals a regulatory strategy aimed at accelerating market entry for its NOCAD-focused product.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that aims to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The latest news and updates relating to CDIO are available in the company's newsroom at https://ibn.fm/CDIO. To view the full press release, visit https://ibn.fm/tEHRV.

The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms of use and disclaimers applicable to all content provided by BioMedWire, visit https://www.BioMedWire.com/Disclaimer.

Burstable Editorial Team

Burstable Editorial Team

@burstable

Burstable News™ is a hosted solution designed to help businesses build an audience and enhance their AIO and SEO press release strategies by automatically providing fresh, unique, and brand-aligned business news content. It eliminates the overhead of engineering, maintenance, and content creation, offering an easy, no-developer-needed implementation that works on any website. The service focuses on boosting site authority with vertically-aligned stories that are guaranteed unique and compliant with Google's E-E-A-T guidelines to keep your site dynamic and engaging.